The m6 A modification of CDKN2 A inhibites ferroptosis and affects the resistance of cervical squamous cell carcinoma to cisplatin

Xiang Yong & Yanzi Qin et al. · 2025-05-15

5Citations
Cervical squamous cell carcinoma (CESC) is the fourth most common malignancy and the fourth leading cause of cancer deaths in women worldwide. Despite advances in treatment, cisplatin-based radiotherapy remains the primary treatment option. However, cisplatin resistance is a major challenge, leading to poor prognosis. Therefore, understanding the molecular mechanisms underlying cisplatin resistance is crucial for developing novel therapeutic strategies. Through bioinformatics analysis, we investigated the expression of CDKN2A in the CESC database. WB, IHC, qPCR, and CCK-8 were used for clinical analysis of CDKN2A expression and its correlation with CESC cell proliferation. Through qPCR, CCK-8, ROS, MDA, Fe
TL;DR

New insights are provided into the molecular mechanisms of cisplatin resistance in CESC and suggest that targeting the METTL3/YTHDF1/CDKN2A axis may be a promising strategy to overcome this resistance and improve treatment outcomes.

AI-generated by Semantic Scholar

Authors
Xiang Yong, Xifeng Xu, Xiaoping Zhang, Rui Song, Huaiyuan Hu, Zhen Li, Yanzi Qin